跳至主要内容
临床试验/NCT01445730
NCT01445730已完成不适用

Fructose Consumption Aggravates Dysregulation of Postprandial Lipid Metabolism in Obese Hypertriglyceridemic Men With High Cardiometabolic Risk Profile and Associates With Liver Fat Deposition

Marja-Riitta Taskinen5 个研究点 分布在 4 个国家目标入组 82 人开始时间: 2011年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
82
试验地点
5
主要终点
TG Plasma AUC

研究概览

简要总结

High fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (CVD). The mechanisms underlying fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. In contrast to metabolism of glucose, the breakdown of fructose leads to the generation of metabolites that stimulate hepatic de novo lipogenesis (DNL) and increased levels of both fasting and postprandial triglycerides. The key lipogenic transcription factor seems to be activated by fructose independently of insulin. However, it is still controversial whether fructose consumption increases DNL in man to the extent that it induces metabolic disturbances. Animal studies have shown that also the adipose tissue is responsive to fructose feeding fructose, and that high fructose-feeding induces insulin resistance and inflammation in the adipose tissue. The role of intestinal insulin resistance in fructose-induced dysmetabolism has not been studied in detail. The critical question is whether the metabolic disturbances are induced by calorie excess or by fructose per se.

详细描述

Detailed description: Study subjects will participate to studies 1-4 before and 3 m after fructose diet:

  1. An oral fat load or a kinetic study with stable isotopes combined with an oral fat load.
  2. Determination of liver, subcutaneous and intra-abdominal fat. (Proton magnetic resonance spectroscopy )
  3. Lipolytic enzymes, advanced lipid analysis, fat biopsies and genetic studies and gut microbiota profiling
  4. Oral glucose tolerance test and analysis of incretins and inflammatory biomarkers.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 60 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Body mass index 27-40
  • Waist > 96 cm
  • Age 20-60 years

排除标准

  • Active health problems
  • Contraindications to MRI scanning
  • Bleeding tendency
  • Abnormal liver or renal function tests
  • Type 2 diabetes
  • Evidence of metabolic or viral liver disease
  • Alcohol intake > 21 units per week
  • Chronic medication except ones needed for stable hypertension

结局指标

主要结局

TG Plasma AUC

时间窗: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)

Before vs. after fructose challenge: Triglycerides (TG) plasma Area Under Curve (AUC)

TG Plasma iAUC

时间窗: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)

Before vs. after fructose challenge:Triglycerides (TG) plasma incremental Area Under Curve (iAUC)

B48 Plasma AUC

时间窗: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)

Before vs. after fructose challenge: apolipoprotein (apo)B48 plasma Area Under Curve (AUC)

次要结局

  • Liver Fat(Form the baseline (time point 1) to end of treatment at 3 months (time point 2))
  • DNL(Form the baseline (time point 1) to end of treatment at 3 months (time point 2))
  • ApoC-III(Form the baseline (time point 1) to end of treatment at 3 months (time point 2))
  • β-OH Butyrate(Form the baseline (time point 1) to end of treatment at 3 months (time point 2))

研究者

发起方
Marja-Riitta Taskinen
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Marja-Riitta Taskinen

Professor

Helsinki University Central Hospital

研究点 (5)

Loading locations...

相似试验